Dr. Christopher M. Maisel, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Pittsburgh School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 356
Licensed in Texas since 2005, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Pittsburgh School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license M2386 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 356
- Services billed
- 33,060
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 7,600 | 28 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,900 | 53 |
| Injection, fosaprepitant, 1 mg | 4,350 | 27 |
| Injection, paclitaxel, 1 mg | 3,438 | 21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 869 | 72 |
| Insertion of needle into vein for collection of blood sample | 530 | 185 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 511 | 182 |
| Injection, palonosetron hcl, 25 mcg | 480 | 43 |
| Injection, granisetron hydrochloride, 100 mcg | 420 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 414 | 162 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 74 |
| Revlimid (lenalidomide) | 61 |
| Hydroxyurea Other prescribers in Dallas, TX | 55 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Dallas, TX | 54 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 42 |
| Lenalidomide | 41 |
| Jakafi (ruxolitinib phosphate) | 37 |
| Eliquis (apixaban) Other prescribers in Dallas, TX | 36 |
| Dexamethasone Other prescribers in Dallas, TX | 32 |
| Xarelto (rivaroxaban) Other prescribers in Dallas, TX | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 65 payments worth $65,767 in total to this clinician.
| Kite Pharma, Inc. | $23,090 |
|---|---|
| Janssen Biotech, Inc. | $11,914 |
| AstraZeneca Pharmaceuticals LP | $9,963 |
| Adc Therapeutics America, Inc. | $9,194 |
| Blueprint Medicines Corporation | $6,094 |
| Sanofi US Services Inc. | $3,906 |
| Genzyme Corporation | $1,166 |
| Geron Corporation | $73.66 |
| Compensation for services other than consulting (speaking, faculty) | $42,177 |
|---|---|
| Honoraria | $14,464 |
| Consulting Fee | $7,325 |
| Food and Beverage | $953 |
| Travel and Lodging | $824 |
| Education | $24.23 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4110162;AHM;10533542 | $5,300 |
| Adc Therapeutics America, Inc. Apr 29, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $4,960 |
| Kite Pharma, Inc. Apr 3, 2025 | Consulting FeeCompany’s description;3969227;GTF;10533542 | $4,450 |
| Sanofi US Services Inc. Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) AYVAKIT · Gastroenterology | $3,790 |
| Janssen Biotech, Inc. Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Janssen Biotech, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Janssen Biotech, Inc. Jul 24, 2025 | Consulting Fee DARZALEX · Oncology | $2,875 |
| Adc Therapeutics America, Inc. Mar 18, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $2,790 |
| Kite Pharma, Inc. Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4110007;AHM;10533542 | $2,650 |
| Kite Pharma, Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4109845;AHM;10533542 | $2,650 |
All 35 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Kite Pharma, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4249288;GTF;10533542 | $1,590 |
| Sanofi US Services Inc. Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) AYVAKIT · Gastroenterology | $3,790 |
| Kite Pharma, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4177161;AHM;10533542 | $2,650 |
| AstraZeneca Pharmaceuticals LP Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| Kite Pharma, Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4177175;AHM;10533542 | $2,650 |
| AstraZeneca Pharmaceuticals LP Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| Janssen Pharmaceuticals, Inc Aug 15, 2025 | Education in-kind | $15.99 |
| Janssen Pharmaceuticals, Inc Aug 15, 2025 | Education in-kind | $8.24 |
| AstraZeneca Pharmaceuticals LP Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| Kite Pharma, Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4109845;AHM;10533542 | $2,650 |
| Janssen Biotech, Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $694 |
| Adc Therapeutics America, Inc. Jul 29, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $620 |
| Janssen Biotech, Inc. Jul 24, 2025 | Consulting Fee DARZALEX · Oncology | $2,875 |
| Genzyme Corporation Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) AYVAKIT · Gastroenterology | $1,166 |
| AstraZeneca Pharmaceuticals LP Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| AstraZeneca Pharmaceuticals LP Jul 9, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $250 |
| Blueprint Medicines Corporation Jun 16, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,166 |
| AstraZeneca Pharmaceuticals LP Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| AstraZeneca Pharmaceuticals LP Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| Kite Pharma, Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4110162;AHM;10533542 | $5,300 |
| Adc Therapeutics America, Inc. Apr 29, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $4,960 |
| Adc Therapeutics America, Inc. Apr 25, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to TYLER, TX | $824 |
| Kite Pharma, Inc. Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4110007;AHM;10533542 | $2,650 |
| AstraZeneca Pharmaceuticals LP Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $1,340 |
| Kite Pharma, Inc. Apr 3, 2025 | Consulting FeeCompany’s description;3969227;GTF;10533542 | $4,450 |
| Adc Therapeutics America, Inc. Mar 18, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $2,790 |
| Blueprint Medicines Corporation Mar 14, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,232 |
| Blueprint Medicines Corporation Mar 3, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,232 |
| Janssen Biotech, Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $833 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $300 |
| Janssen Biotech, Inc. Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Kite Pharma, Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;3913026;GTF;10533542 | $1,060 |
| Blueprint Medicines Corporation Jan 9, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,232 |
| Blueprint Medicines Corporation Jan 9, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $1,232 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $290,692 in research payments for these studies, mostly to the institutions running them.
- A randomized 2ARM phase 3 study of elranatamab PF06863135 versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stemcell transplantation
Pfizer Inc. - MAGNETISMM3 an openlabel multicenter nonrandomized phase 2 study of elranatamab PF06863135 monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor one immunomodulatory…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.